Skip to main content
Premium Trial:

Request an Annual Quote

Beckman s Q1 Revenues Up 7 Percent, Profit Jumps 16 Percent

NEW YORK, May 4 (GenomeWeb News) - Beckman Coulter today reported a 7-percent increase in first-quarter revenues and a 16-percent jump in net earnings.

 

Revenues for the quarter ended March 31 increased to $576.1 million from $536.8 million during the same period last year. Both the company's Clinical Diagnostics and Biomedical Research divisions contributed about equally to this increase.

 

Research and development costs remained flat at $48 million.

 

Beckman's net income for the quarter increased to $41.4 million, or $.62 per share, from $35.6 million, or $.54 per share, during the same period last year.

 

As of March 31, Beckman Coulter had $105.2 million in cash and cash equivalents.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.